RGD肽类似物应用于恶性黑色素瘤诊疗的研究进展
Advances on RGD Peptide Analogs for Diagnosis and Therapy of Malignant Melanoma
黄志洪 1王玲 1薛岩 1朱雪 1王柯1
作者信息
- 1. 南京医科大学药学院核药学系,江苏南京 211166;国家卫生健康委员会核医学重点实验室,江苏省分子核医学重点实验室,江苏省原子医学研究所,江苏无锡 214063
- 折叠
摘要
恶性黑色素瘤是一种高度恶性且易于转移的致命癌症,其预后与肿瘤早期诊断及精准治疗密切相关.整合素的异常表达与恶性黑色素瘤的发生及进展密切相关,介导了肿瘤的增殖、侵袭和转移,并与不良预后密切相关.以精氨酸-甘氨酸-天冬氨酸(Arg-Gly-Asp,RGD)为基序的RGD肽类似物可特异性结合整合素,从而实现肿瘤的精准诊疗.全文基于RGD肽类似物的来源和分类,对其应用于恶性黑色素瘤诊疗的研究进展展开综述.
Abstract
Malignant melanoma is a highly aggressive cancer characterized by high rates of metastasis and mortality.The prognosis of malignant melanoma is closely related to early diagnosis and accurate treat-ment.The abnormal expression of integrins occurs during the development and progression of malignant melanoma,which mediated tumor proliferation,invasion,and metastasis,and is closely associated with a poor prognosis.RGD peptide analogs,which utilize the arginine-glycine-aspartate(Arg-Gly-Asp)motif,can specifically bind to integrins,facilitating accurate diagnosis and targeted treatment of malignant tu-mors.This paper reviews the research advances on the sources and classification of RGD peptide analogs and their application in diagnosis and treatment of malignant melanoma.
关键词
恶性黑色素瘤/整合素/RGD肽类似物/早期诊断/靶向治疗Key words
malignant melanoma/integrin/RGD peptide analogues/early diagnosis/targeted therapy引用本文复制引用
基金项目
江苏省中医药科技发展计划项目(MS2023166)
江苏省卫生健康委科研项目(H2023150)
无锡市卫生健康委科研项目(Z202303)
出版年
2024
NETL
NSTL
万方数据